Ipilimumab vs Metformin
Ipilimumab vs Metformin: Overview
This comparison examines the pharmacological differences between Ipilimumab and Metformin.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Metformin: Activates AMP-activated protein kinase, decreasing hepatic glucose production.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Metformin β 4-9 hours.
Chemical Properties
Molecular Formula: Metformin β C4H11N5.
Molecular Weight: Metformin β 129.1640 g/mol.
Type: Ipilimumab β Antibody; Metformin β Small molecule.